Want to see SE:CARA full AI Analyst Report?
CARA Stock Chart & Stats
kr29.00
-kr0.28(-1.22%)
At close: 4:00 PM EST
kr29.00
-kr0.28(-1.22%)
Day’s Range― - ―
52-Week Rangekr21.70 - kr30.55
Previous CloseN/A
Volume42.56K
Average Volume (3M)175.33K
Market Cap
kr1.61B
Enterprise Valuekr1.45B
Total Cash (Recent Filing)kr51.43M
Total Debt (Recent Filing)kr28.66M
Price to Earnings (P/E)38.9
Beta0.06
Next Earnings
Oct 15, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding70,324,780
10 Day Avg. Volume229,351
30 Day Avg. Volume175,329
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.45
Revenue Forecast (FY)kr410.33M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage (debt-to-equity ~0.04) gives durable financial flexibility: supports investment in product development or M&A, reduces solvency risk in downturns, and permits prioritizing organic growth or opportunistic capital allocation without jeopardizing operations.
Recovered ProfitabilityReturn to positive EBITDA and net margins indicates the business model is generating sustainable operating profits. Healthy EBITDA (~22.5%) supports reinvestment, margins resiliency, and long-term ability to fund R&D and support services while maintaining core software economics.
Improving Cash GenerationStrong recent operating cash flow and sizable positive FCF provide durable internal funding for product enhancements and customer success. Improving FCF (~51.1M) and growth (~35%) lower reliance on external financing and improve optionality for strategic investments over the medium term.
Bears Say
Slowing Revenue GrowthA marked slowdown in top-line growth versus prior high-growth years reduces the levered upside of software economics. Slower revenue expansion limits operating leverage, constrains scale benefits across R&D and sales, and makes meeting future margin targets more dependent on efficiency gains.
Modest Operating ReturnsLow EBIT margin and weak ROE suggest the company is not yet efficiently converting operating profits into shareholder returns. Persistently low returns reduce capital allocation flexibility and may require sustained margin improvement or higher growth to justify reinvestment.
Inconsistent Cash ConversionVolatile conversion of net income to free cash flow implies working-capital swings or timing of investments. This reduces predictability of internally generated funds for strategic initiatives, and heightens sensitivity to execution and billing cycles over the medium term.
Carasent AB News
CARA FAQ
What was Carasent AB’s price range in the past 12 months?
Carasent AB lowest stock price was kr21.70 and its highest was kr30.55 in the past 12 months.
What is Carasent AB’s market cap?
Carasent AB’s market cap is kr1.61B.
When is Carasent AB’s upcoming earnings report date?
Carasent AB’s upcoming earnings report date is Oct 15, 2026 which is in 87 days.
How were Carasent AB’s earnings last quarter?
Carasent AB released its earnings results on Jul 10, 2026. The company reported -kr0.04 earnings per share for the quarter, missing the consensus estimate of kr0.023 by -kr0.063.
Is Carasent AB overvalued?
According to Wall Street analysts Carasent AB’s price is currently Overvalued.
Does Carasent AB pay dividends?
Carasent AB pays a Notavailable dividend of kr1.84 which represents an annual dividend yield of N/A. See more information on Carasent AB dividends here
What is Carasent AB’s EPS estimate?
Carasent AB’s EPS estimate is 0.13.
How many shares outstanding does Carasent AB have?
Carasent AB has 70,324,780 shares outstanding.
What happened to Carasent AB’s price movement after its last earnings report?
Carasent AB reported an EPS of -kr0.04 in its last earnings report, missing expectations of kr0.023. Following the earnings report the stock price went up 7.253%.
Which hedge fund is a major shareholder of Carasent AB?
Currently, no hedge funds are holding shares in SE:CARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Technical Analysis
EQL Pharma AB
―
Vicore Pharma Holding AB
―
Humana AB
―
Xspray Pharma AB
―
Sedana Medical AB
―